WuXi Biologics (Cayman) Inc (fra:1FW2) Share Price

Company Profile

Business description
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing, refining, and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
Contact
No. 108, Meiliang Road
Mashan Binhu District
Wuxi214092
CHN
https://www.wuxibiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13,252

Recommended

Short term margin pressure yet shares remain undervalued on improved outlook.

Angus Hewitt, CFA | 14 September 2026

A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.

Larry Swedroe | 13 September 2026

Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.

Krzysztof Smalec, CFA | 13 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,849.30	74.60	-0.84%
CAC 40	8,090.09	27.69	-0.34%
DAX 40	25,405.06	35.75	-0.14%
Dow JONES (US)	51,897.00	524.20	-1.00%
FTSE 100	10,650.84	46.73	-0.44%
HKSE	24,667.24	250.36	-1.00%
NASDAQ	26,003.81	182.60	-0.70%
Nikkei 225	63,484.10	8.89	-0.01%
NZX 50 Index	13,484.22	76.47	-0.56%
S&P 500	7,581.15	38.83	-0.51%
S&P/ASX 200	8,672.50	77.40	-0.88%
SSE Composite Index	3,864.28	21.05	-0.54%